Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 1,307 trials

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Protecting Children from Radiation-Induced Hypothyroidism

We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.

Hodgkin and Non-Hodgkin LymphomaMedulloblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

IgA Nephropathy: Hydroxychloroquine Study

We are studying whether Hydroxychloroquine can help slow kidney function decline in patients with IgA Nephropathy. This trial focuses on those with high levels of protein in their urine despite current treatments.

IgA Nephropathy>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineNephrology

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Advanced Melanoma: EIK1001 and Pembrolizumab Study

We are studying a new treatment combining EIK1001 with pembrolizumab for patients with advanced melanoma. The goal is to see if this combination improves survival and slows disease progression compared to a placebo.

Advanced Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteOncology

Anticoagulant Treatments for Intra-Cardiac Thrombus: The ARGONAUT Trial

We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.

Intracardiac Thrombus>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Acute Myeloid Leukemia: Revumenib with Azacitidine and Venetoclax

We are studying whether adding revumenib to azacitidine and venetoclax helps adults with newly diagnosed NPM1-mutated AML who cannot receive intensive chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid LeukemiaConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Migraine Treatment in Kids: Rimegepant Study

We are studying the effectiveness of rimegepant for treating migraines in children and adolescents aged 6 to under 18. The goal is to see if it helps relieve pain and other symptoms better than a placebo.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteNeurologyPediatrics

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Acute Myeloid Leukemia: Ivosidenib, Azacitidine, and Venetoclax Study

We are investigating whether adding venetoclax to ivosidenib and azacitidine helps patients with newly diagnosed IDH1-mutated AML who cannot undergo intensive chemotherapy. The goal is to see if this combination improves survival and remission rates.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Remyelination in Multiple Sclerosis: PET-MR Study

We are investigating how myelin repair happens in people with multiple sclerosis using advanced imaging techniques. This study aims to understand the role of neuroinflammation in the repair process.

Progressive Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Neurology

Pancreatic Exocrine Insufficiency: Creon® Therapy

We are studying how well Creon® helps patients with pancreatic exocrine insufficiency after surgery. The goal is to see if it improves symptoms and nutritional health.

Pancreatic Exocrine Insufficiency6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine